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We should do better. I think by and large chlortha-
lidone or indapamide have a renaissance.
The other issue to be considered is that we were 
so convinced that ACEIs and ARBs are the way to 
go that we almost forgot that calcium channel 
blockers (CCBs) are as efficacious—if not more 
efficacious—than ACEIs and ARBs, and we know 
now that amlodipine and to some extent nifedip-
ine are very well-documented drugs that have ex-
cellent outcome data and have been shown to re-
duce morbidity, mortality, heart attack, stroke, 
and death, in some cases even better than the 
ACEIs and ARBs.
In a nutshell, what we do know is that chlortha-
lidone or indapamide as diuretics, amlodipine 
and nifedipine as CCBs, and the ARBs and ACEIs 
are all suitable for first-time therapy. Clearly we 
have learned that β-blockers are no longer in that 
position.
A loaded question but an incredibly informative an-
swer. The notion that hydrochlorothiazide data are 
almost nonexistent but those for chlorthalidone and 
indapamide are available is revolutionary for most 
of the primary practitioners, including myself. The 
dose of chlorthalidone would be similar to that of 
hydrochlorothiazide?
Actually no, it is about half. We just recently pub-
lished a paper in the Journal of the American Col-
lege of Cardiology1 showing that 6.25 mg is a de-
cent antihypertensive dose of chlorthalidone. So 
you can use a minimal dose. In the US, we actually 
have the problem that the lowest dose available is 
25 mg, so if you break the tablet it usually crum-
bles, but I tell my patients, “Just take a crumb.”
McMaster Perspective This interview is part of 
the McMaster Perspective collection. The video 
can be viewed at www.mcmtextbook.com. Pub-
lished with modifications with permission from 
Dr. Franz H. Messerli.
Professor Messerli, you are the person who led the 
treatment of hypertension over the last few decades. 
I would like to ask you to reflect on the last few de-
cades of hypertensive treatment. Where did we start, 
where are we now?
That is actually a very loaded question and not 
easy to answer. If you go back to the guidelines, 
you have to consider that for years and decades 
the dictum was thiazide diuretics. First it was thi-
azide diuretics, and then it was low-dose thiazide 
diuretics. To the practicing physician in the Unit-
ed States this very simply means hydrochloro-
thiazide. So a few years back I decided to look at 
the data—what data do we have for hydrochlo-
rothiazide? Surprise, surprise: we have no data 
for hydrochlorothiazide showing that in a low 
dose of 12.5 to 25 mg it reduces heart attacks, 
stroke, or death. So what these guidelines had 
been telling practicing physicians was all based 
on either chlorthalidone (INN chlortalidone) or 
indapamide, yet these two drugs are not used 
in the US—they are only about 1% of diuretics 
used—so clearly what was taught by the guide-
lines in the past was deceptive.
Now we are realizing finally that we should go 
with the evidence and we should use chlorthali-
done, we should use indapamide, and not hydro-
chlorothiazide. Unfortunately, those fixed com-
binations—that is β-blockers, angiotensin-con-
verting enzyme inhibitors (ACEIs), and angioten-
sin receptor blockers (ARBs)—are fixed together 
with hydrochlorothiazide, because pharmaceutical 
companies were exactly under the same influence. 
They had the idea hydrochlorothiazide is the way 
to go. Now we are learning it is not necessarily so. 
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